Trial · NCT06715007
Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
NCT06715007, Recruiting, The First Affiliated Hospital with Nanjing Medical University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases. Trials, record NCT06715007. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06715007
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Antiplatelet Therapy and Endothelial-stabilizing Agents in Cerebral Small Vessel Diseases
- NCT number
- NCT06715007
- Status
- Recruiting
- Enrollment
- 300 participants, estimated
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Conditions
- Stroke, Ischemic, Small Vessel Cerebrovascular Disease, White Matter Hyperintensity
- Interventions
- Clopidogrel, Aspirin, Cilostazol + Isosorbide Mononitrate
- First posted
- 2024-12-04
- Last updated
- 2025-03-28
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | the impact of different antiplatelet agents on retinal vasculature. | 6 months follow up | retinal vasculature will be assessed by optical coherence tomography and optical coherence tomography angiography. |
| Secondary | systemic or intracranial bleeding | systemic or intracranial bleeding will be assessed during 6 month follow-up. | |
| Secondary | occurrence of ischemic stroke or transient ischemic attack | during 6 month follow-up | |
| Secondary | Neurological function | Neurological function will be assessed at baseline, 1 week, 3 months and 6-month after recruitment. | Neurological function will be assessed by NIHSS (National institute of health stroke scale) |
| Secondary | Brain MRI (magnetic resonance imaging) | Brain MR will be performed at baseline and at 6 months after recruitment | Brain MRI to evaluate whiter matter hyperintensities. |
| Secondary | Cognitive function | MoCA will be assessed at baseline and at 3 and 6 months after recruitment. | Montreal cognitive assessment (MoCA) will be used. |
| Secondary | modified Rankin Scale (mRS) score | modified Rankin Scale (mRS) score will be assessed at baseline and at 3 and 6 months after recruitment. | |
| Secondary | Barthel index for activities of daily living | Barthel index will be assessed at baseline, 3 and 6 months after recruitment. | Barthel index for activities of daily living is an ordinal scale which measures a person's ablility to complete activities of of daily living. |
| Secondary | Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) | UPDRS score will be evaluated at baseline and 3, 6 months after recruitment. | MDS-UPDRS is scale to evaluate various aspects Parkinson's disease or Parkinsonism including non-motor and motor experiences of daily living and motor complications. Small vessel diseases may cause Parkinsonism, we thus use this scale in our study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06715007
GET https://conductscience.org/api/trials/v1/NCT06715007/registered